SARS-CoV-2 vaccination of people living with human T leukaemia virus type 1

dc.creatorAraujo, Abelardo
dc.creatorMartin, Fabiola
dc.date2022-01-24T13:39:32Z
dc.date2022-01-24T13:39:32Z
dc.date2021
dc.date.accessioned2023-09-26T21:04:13Z
dc.date.available2023-09-26T21:04:13Z
dc.identifierARAUJO, Abelardo; MARTIN, Fabiola. SARS-CoV-2 vaccination of people living with human T leukaemia virus type 1. Sexually Transmitted Infections, v. 0, p. 1, 2021.
dc.identifier0148-5717
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/50855
dc.identifier10.1136/sextrans-2021-055007
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8868652
dc.descriptionSeveral SARS-CoV-2 vaccines are being rolled out worldwide, following testing in healthy volunteers and smaller groups of people with comorbidities, including HIV. Human T-cell leukaemia virus type 1 (HTLV-1), a retrovirus like HIV, is oncogenic and can cause chronic immune dysfunction. However, there is no established antiretroviral treatment for HTLV-1. An estimated 10 million individuals live with HTLV-1 worldwide. Two main disease patterns are recognised: lymphoproliferative immunodeficient (adult T-cell leukaemia/lymphoma) and inflammatory immunodysfunctional (HTLV-1-associated myelopathy).
dc.formatapplication/pdf
dc.languageeng
dc.publisherBMJ
dc.rightsopen access
dc.subjectSARS-CoV-2
dc.subjectCOVID-19
dc.subjectVaccine
dc.subjectATL
dc.subjectHAM/TSP
dc.subjectHTLV
dc.titleSARS-CoV-2 vaccination of people living with human T leukaemia virus type 1
dc.typeArticle


Este ítem pertenece a la siguiente institución